“Ubiquitin-Mediated Proteolysis and Cell Sensitivity to Camptothecin”

Hervé Jacquiau, J.D., Ph.D., M.Sc., D.E.A.

Hervé Jacquiau, Ph.D. co-authored this article discussing Camptothecin (CPT) stabilizes a covalent DNA topoisomerase I (Top1 p)-DNA complex that is converted into irreversible lesions in S-phase and induces cell death. To define cellular processes that recognize and repair CPT-induced lesions, a yeast genetic screen to isolate mutants with enhanced sensitivity to Top1p poisons at 35°C was developed.

Hervé Jacquiau, Ph.D., assists in all aspects of patent practice, including patent prosecution and litigation. His background covers a variety of technologies, particularly biotechnology, bioengineering, biochemistry, molecular biology and microbiology. Hervé received his Ph.D. degree from the University of Cambridge after investigating the genetic and biochemical features responsible for the biodegradation of toxic pollutants.